neurocrine biosciences inc
(NBIX:NASDAQ GS)
neurocrine biosciences inc (NBIX) Snapshot
|
Open
$12.02
|
Previous Close
$11.99
|
|
|
Day High
$12.10
|
Day Low
$11.68
|
|
|
52 Week High
04/3/13 - $12.85
|
52 Week Low
05/29/12 - $6.25
|
|
|
Market Cap
784.1M
|
Average Volume 10 Days
671.9K
|
|
|
EPS TTM
$-0.11
|
Shares Outstanding
66.7M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
neurocrine biosciences inc (NBIX) Related Businessweek News
No Related Businessweek News Foundneurocrine biosciences inc (NBIX) Details
Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company’s products in clinical development include Elagolix, a Phase III drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF2 Peptide Agonist, a Phase II drug for cardiovascular diseases; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for schizophrenia; gonadotropin-releasing hormone (GnRH) Antagonists for men’s and women’s health, and oncology; Antiepileptic Drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled Receptors for other conditions. The company has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women’s and men’s health; Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of Type II diabetes and other indications; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
neurocrine biosciences inc (NBIX) Top Compensated Officers
neurocrine biosciences inc (NBIX) Key Developments
Neurocrine Biosciences Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the first quarter of 2013, the company reported net loss of $12.1 million, or $0.18 per basic and diluted share, compared to a net loss of $0.9 million, or $0.01 per basic and diluted share, for the same period in 2012. Revenues were $0.7 million compared with $11.3 million for the same period last year. The entire $10.6 million reduction in revenue is due to the successful completion of the sponsored research and development segments of the company's license agreements with both AbbVie and Boehringer Ingelheim during 2012, as scheduled. Loss from operations was $13 million against $1.8 million a year ago. For the year 2013, the company expects approximately $3 million in revenue from upfront license fee amortization, and expenses should approximate $55 million to $60 million. Net loss is expected to be $50 million to $55 million.
Neurocrine Biosciences Inc. announced that they will report Q1, 2013 results at 5:00 PM, Eastern Standard Time on May 02, 2013
Neurocrine Biosciences Inc., Q1 2013 Earnings Call, May 02, 2013
| Recently Viewed | |||
| NBIX:US | $11.75 USD | -0.24 |  |
| Company | Last | Change |
| Cumberland Pharmaceuticals Inc | $4.94 USD | -0.01 |
| Horizon Pharma Inc | $2.40 USD | -0.01 |
| Pain Therapeutics Inc | $2.89 USD | +0.09 |
| Pozen Inc | $4.90 USD | +0.04 |
| Synta Pharmaceuticals Corp | $7.50 USD | +0.01 |
| View Industry Companies | ||
Industry Analysis
NBIX
Industry Average
| Valuation | NBIX | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 18.7x |
|
| Price/Book | 5.5x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 15.1x |
|
Post a JobJobs
Sponsored Financial Commentaries
Sponsored Links
To contact NEUROCRINE BIOSCIENCES INC, please visit www.neurocrine.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
